HCKT
The Hackett Group, Inc.
HCKT's outlook is improving, though it still trails on the overall score.
NVDA
NVIDIA Corporation
NVDA has the edge over HCKT overall, supported by stronger valuation and stronger modeled upside.
HCKT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Strong | |
| Stable | |
| Stable |
HCKT's profitability is currently strong, and its cash flow and balance sheet are stable, but its revenue is under pressure.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
HCKT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 8.7x | $13.44 | — |
| Cheap | 16x | $11.45 | -15% |
| Current | 19x | $13.44 | — |
| Fair | 21x | $14.55 | +8.2% |
| Expensive | 39x | $26.96 | +101% |
Historical ranges are pointers, not guarantees.
HCKT's PE is in its fair range at 19x. If earnings grow as analysts expect, today's price would be 8.7x next year's earnings, in its cheap range.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over HCKT in the historical PE scenario, which offers more potential upside but is not a forecast.
HCKT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect HCKT's earnings to grow and its profitability to improve, with its revenue holding steady.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
HCKT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.55 | +121% |
| Q3 2026 | $0.70 | +84% |
| Q2 2026 | $0.65 | +8.3% |
| Q1 2026 | $0.53 | -38% |
| Q4 2025 | $0.47 | -56% |
| Q3 2025 | $0.38 | -69% |
| Q2 2025 | $0.60 | -52% |
| Q1 2025 | $0.85 | -33% |
| Q4 2024 | $1.06 | -15% |
HCKT's earnings per share have fallen from their peak: $0.70 over the past year, against $1.47 in late 2022.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over HCKT on earnings, with more consistent year-over-year improvement.
HCKT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $69.8M | -4.5% |
| Q2 2026 | $69.3M | -12% |
| Q1 2026 | $68.8M | -12% |
| Q4 2025 | $75.8M | -4.4% |
| Q3 2025 | $73.1M | -8.4% |
| Q2 2025 | $78.9M | +1.6% |
| Q1 2025 | $77.9M | +0.9% |
| Q4 2024 | $79.2M | +9.4% |
HCKT's revenue is shrinking: $70M last quarter, down 4.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | +3.3 points |
| Q2 2026 | 11% | +5.3 points |
| Q1 2026 | 13% | +7.3 points |
| Q4 2025 | 12% | +2.2 points |
| Q3 2025 | 7.5% | -8.6 points |
| Q2 2025 | 5.8% | -10 points |
| Q1 2025 | 5.7% | -9.3 points |
| Q4 2024 | 9.8% | -6.1 points |
HCKT's operating margin was 11% last quarter, up 3.3 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over HCKT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over HCKT on profitability, with a higher operating margin.
HCKT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.3M | -115% |
| Q2 2026 | $12.6M | +237% |
| Q1 2026 | -$7.5M | -382% |
| Q4 2025 | $17.1M | -13% |
| Q3 2025 | $9M | -3.9% |
| Q2 2025 | $3.7M | -71% |
| Q1 2025 | $2.7M | +44% |
| Q4 2024 | $19.6M | -21% |
HCKT usually generates cash, though not every quarter: the latest was −$1M, but it generated $21M over the past year.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over HCKT on cash flow, with more consistent year-over-year improvement.
HCKT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -213K shares |
| 1 year | -9.6% | -2.7M shares |
| 3 years | -10% | -2.9M shares |
| 5 years | -24% | -7.9M shares |
| Available history | -23% | -7.5M shares |
HCKT has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.8M |
| Q2 2026 | $3.9M |
| Q1 2026 | $3M |
| Q4 2025 | $41.2M |
| Q3 2025 | $17.4M |
| Q2 2025 | $4.3M |
| Q1 2025 | $6.2M |
| Q4 2024 | $3.6M |
HCKT spent $50M buying back its own shares over the past year, up 58% from the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
HCKT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.9x | Healthy |
| Q2 2026 | 1.8x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.0x | Moderate |
| Q3 2025 | 1.1x | Healthy |
| Q2 2025 | 0.4x | Very low |
| Q1 2025 | 0.2x | Very low |
| Q4 2024 | -0.1x | Net Cash |
HCKT's net debt is about 1.9 years of its operating earnings (EBITDA), up from 1.1 years a year ago.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA has the edge over HCKT on leverage, with a lower net debt burden relative to earnings.
HCKT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.5 | Neutral |
| Stochastic | 84.5 | Overbought |
HCKT's weekly RSI is 60 (neutral) and its Stochastic is 84 (overbought).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
HCKT PE vs Technology Sector
| Metric | HCKT | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 28x | 31% below |
| PE % | 38 | 35 | 3 pts above |
HCKT has the edge over NVDA on valuation relative to its sector.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
HCKT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.9 | 13% above |
| 20 week MA | $11.2 | 20% above |
| 50 week MA | $13.3 | 1% above |
| 100 week MA | $19.0 | 29% below |
| 200 week MA | $21.0 | 36% below |
HCKT has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
HCKT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.9 | $14.0 | -12% |
| 2021 | $14.0 | $20.7 | +47% |
| 2022 | $20.7 | $20.5 | -0.8% |
| 2023 | $20.5 | $22.8 | +11% |
| 2024 | $22.8 | $30.9 | +36% |
| 2025 | $30.9 | $20.0 | -35% |
| 2026 YTD | $20.0 | $13.4 | -33% |
HCKT has finished lower in three of the last six years. It's down 33% so far in 2026.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA has the edge over HCKT on returns for 2026, with the stronger performance.